Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monotherapy With Piperacillin-tazobactam Versus Combination Therapy With Piperacillin-tazobactam Plus Glycopeptide as an Initial Empiric Therapy for Fever in Neutropenic Patients. An Observational Prospective Study.

NCT00195533 is registered in ClinicalTrials.gov with Wyeth is now a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT00195533
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00195533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monotherapy With Piperacillin-tazobactam Versus Combination Therapy With Piperacillin-tazobactam Plus Glycopeptide as an Initial Empiric Therapy for Fever in Neutropenic Patients. An Observational Prospective Study.
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Phase
Observational
Overall status
Completed
Start date
July 31, 2001
Completion date
March 31, 2005
Enrollment
801 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

hematological malignancy, leukemia, lymphoma, myelodysplasia, myeloma, stem cell transplantation